Among 2 analysts covering NewLink Genetics (NASDAQ:NLNK), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. NewLink Genetics had 2 analyst reports since March 23, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, March 23 by Robert W. Baird. The firm has “Neutral” rating by SunTrust given on Wednesday, May 11. See NewLink Genetics Corp (NASDAQ:NLNK) latest ratings:
The stock of Relx NV (ADR) (NYSE:RENX) gapped down by $0.05 today and has $17.95 target or 3.00% below today’s $18.51 share price. The 9 months technical chart setup indicates high risk for the $39.54 billion company. The gap down was reported on Mar, 29 by Barchart.com. If the $17.95 price target is reached, the company will be worth $1.19B less. The stock decreased 0.43% or $0.08 on March 29, reaching $18.51. About 86,260 shares traded. Relx NV (ADR) (NYSE:RENX) has risen 4.20% since August 22, 2016 and is uptrending. It has underperformed by 3.86% the S&P500.
RELX NV is a holding company, which holds interests in RELX Group plc. The company has market cap of $39.54 billion. RELX Group is a global well-known provider of information and analytics for professional and business clients across industries. It has a 40.93 P/E ratio. The Firm operates in four divisions: Scientific, Technical & Medical; Risk & Business Analytics; Legal, and Exhibitions.
About 475,942 shares traded or 29.53% up from the average. NewLink Genetics Corp (NASDAQ:NLNK) has risen 100.10% since August 22, 2016 and is uptrending. It has outperformed by 92.04% the S&P500.
